Somewhat Favorable News Coverage Somewhat Unlikely to Affect Cumberland Pharmaceuticals (CPIX) Stock Price

News stories about Cumberland Pharmaceuticals (NASDAQ:CPIX) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cumberland Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 47.0819617436028 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Cumberland Pharmaceuticals (CPIX) opened at $7.11 on Friday. The firm has a market capitalization of $111.50, a PE ratio of -14.22 and a beta of 0.85. The company has a current ratio of 4.18, a quick ratio of 3.81 and a debt-to-equity ratio of 0.12. Cumberland Pharmaceuticals has a 12-month low of $5.28 and a 12-month high of $7.96.

Separately, ValuEngine lowered Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Cumberland Pharmaceuticals (CPIX) Stock Price” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cumberland-pharmaceuticals-cpix-stock-price.html.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply